Enliven Therapeutics (NASDAQ:ELVN) Shares Up 5.3% – Should You Buy?

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) rose 5.3% during trading on Thursday . The stock traded as high as $28.99 and last traded at $28.6850. Approximately 1,011,814 shares traded hands during mid-day trading, a decline of 7% from the average daily volume of 1,086,826 shares. The stock had previously closed at $27.25.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ELVN. Wall Street Zen cut Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $41.00.

Enliven Therapeutics Stock Up 12.6%

The stock has a 50-day moving average price of $27.43 and a 200 day moving average price of $22.34. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of -16.73 and a beta of 0.33.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.06). As a group, equities analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Richard A. Heyman sold 9,635 shares of Enliven Therapeutics stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $25.03, for a total transaction of $241,164.05. Following the sale, the director directly owned 25,545 shares in the company, valued at $639,391.35. This trade represents a 27.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joseph P. Lyssikatos sold 91,198 shares of the company’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.22, for a total transaction of $2,482,409.56. Following the completion of the transaction, the insider owned 765,188 shares of the company’s stock, valued at $20,828,417.36. This represents a 10.65% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 237,180 shares of company stock worth $6,301,233. Insiders own 25.90% of the company’s stock.

Institutional Trading of Enliven Therapeutics

A number of large investors have recently made changes to their positions in ELVN. Vestal Point Capital LP grew its position in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after acquiring an additional 2,670,000 shares during the last quarter. TCG Crossover Management LLC purchased a new position in Enliven Therapeutics during the 2nd quarter worth $9,990,000. Duquesne Family Office LLC increased its stake in Enliven Therapeutics by 104.6% in the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock valued at $19,393,000 after purchasing an additional 484,405 shares during the period. Spruce Street Capital LP purchased a new stake in shares of Enliven Therapeutics in the fourth quarter valued at about $6,870,000. Finally, Polar Capital Holdings Plc boosted its stake in shares of Enliven Therapeutics by 13.5% during the fourth quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock worth $54,111,000 after buying an additional 418,673 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.